SHEIN's Science-Based Net-Zero Target is Approved by SBTi
SINGAPORE, May 27, 2025 /PRNewswire/ -- As a global online fashion and lifestyle retailer, we have reached a milestone in our climate journey with the Science Based Targets initiative (SBTi) validating our net-zero science-based target by 2050 and...
Wiltson's Revolutionary Low-Temperature Battery Tech Conquers Mount Everest, Unlocking Extreme Reliability for Demanding US Power Applications
DONGGUAN, China, May 27, 2025 /PRNewswire/ -- Wiltson Energy, a leading innovator in low-temperature lithium battery technology, today announced a groundbreaking achievement, demonstrating unmatched reliability for demanding power solutions in the...
Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain
HEIDELBERG, Germany, May 12, 2025 /PRNewswire/ -- A groundbreaking international study has mapped over 400 distinct human cell types, providing powerful validation for Prof. Mike Chan's longstanding vision of organ-specific, cell-specific...
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for...
Telix Adds Lead-212 Isotope Production Capability
MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the...
Huawei's Smart String & Grid Forming ESS Triumphs in Extreme Ignition Test
SHENZHEN, China, March 6, 2025 /PRNewswire/ -- Huawei Digital Power's Smart String & Grid Forming Energy Storage System (ESS) has successfully passed the extreme ignition test, witnessed by customers and DNV, a globally recognized independent...
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM...